Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RubaXX
- Development stage
- Unknown
- Lead developer
- PharmaSGP
- Modality
- Small Molecules
- Administration
- Oral, Topical
01
Overview
RubaXX is a line of over-the-counter (OTC) natural pharmaceutical products developed and marketed by PharmaSGP for the treatment of rheumatic pain. The flagship product, RubaXX drops, contains the active ingredient *Toxicodendron quercifolium* (also known as *Rhus toxicodendron*) in a homeopathic dilution (D6). It is indicated for rheumatic pain in bones, joints, tendons, and muscles, as well as the consequences of injuries and overexertion. The product line also includes specialized formulations like RubaXX Arthro (containing *Viscum album* for osteoarthritis), RubaXX Duo (containing *T. quercifolium* and *Phytolacca americana*), and RubaXX Gicht (containing colchicine for gout). RubaXX is marketed as a chemical-free alternative to conventional painkillers and is a market leader in the systemic natural pain relief segment in Germany and other European countries.
- Brand names
- RubaXXRubaXX dropsRubaXX SchmerzgelRubaXX ArthroRubaXX DuoRubaXX Gicht
- Other names
- Toxicodendron quercifoliumRhus toxicodendron
Beyond the preview
Go deeper on RubaXX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RubaXX.